The economic burden of dengue fever in the Kingdom of Saudi Arabia

PLoS Negl Trop Dis. 2020 Nov 30;14(11):e0008847. doi: 10.1371/journal.pntd.0008847. eCollection 2020 Nov.

Abstract

Rapid urbanization, global trade, and the exceptionally great numbers of worldwide visitors during Hajj and Umrah have all placed the Kingdom of Saudi Arabia at a significant risk of introducing several vector-borne tropical diseases, such as dengue fever virus (DENV) infection. In this study we estimated DENV infection cost of illness (COI) in Saudi Arabia in the period 2013-2017, by processing national data including all declared cases recorded in referral centers in the western region, being the endemic region of the country. Using a statistically validated predictive model that was built on a representative sample of 717 laboratory-confirmed cases of DENV infection, direct costs, due to care-related expenditures, were estimated by applying the predictive equation to national data. However, indirect costs, which are due to productivity loss, were estimated using the human capital model based on gross domestic product adjusted for invalidity duration. Further, under-reporting was adjusted by using an expansion factor EF = 3. We observed highest estimated costs in 2016 with over US$168.5 Million total costs, including direct (US$29.0 Million) and indirect (US$139.5 Million) costs, for a total 4415 confirmed cases. The total DENV COI for the five years was estimated as US$551.0 Million for a total 15,369 patients (59.7%) out of 25,745 declared cases, resulting in an average cost of US$11 947.6 by patient. Depending on the year, productivity years loss costs accounted for 63.3% to 83.8% of the estimated total costs. Dengue has a substantial local economic burden that costs US$110.2 Million per year, stressing the urgent need for an effective national prevention strategy to perform considerable cost-savings besides reducing morbidity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Cost of Illness*
  • Dengue / economics*
  • Dengue / epidemiology*
  • Dengue Virus / isolation & purification
  • Female
  • Health Care Costs / statistics & numerical data*
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Saudi Arabia / epidemiology

Grants and funding

This study was funded by Sanofi Pasteur (Lyon, France) under the registration number Clinical Trial – DNG19-EXT to NA and OS.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.